Insight Molecular Diagnostics (IMDX) Cash & Equivalents (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Cash & Equivalents data on file, last reported at $28.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 9.03% year-over-year to $28.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.2 million (down 9.03% YoY) and the FY2025 annual result came in at $11.6 million, up 34.12% from the prior year.
• Cash & Equivalents rose to $28.2 million in Q1 2026 per IMDX's latest filing, from $11.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $44.8 million in Q2 2022, with the low at $433000.0 in Q4 2022.
• Average Cash & Equivalents over 5 years is $17.1 million, with a median of $13.8 million recorded in 2023.
• Year-over-year, Cash & Equivalents sank 98.69% in 2022 and soared 2078.29% in 2023.
• Insight Molecular Diagnostics' Cash & Equivalents stood at $433000.0 in 2022, then soared by 2078.29% to $9.4 million in 2023, then dropped by 8.44% to $8.6 million in 2024, then jumped by 34.12% to $11.6 million in 2025, then surged by 143.47% to $28.2 million in 2026.
• Business Quant data shows IMDX's Cash & Equivalents at $28.2 million in Q1 2026, $11.6 million in Q4 2025, and $18.7 million in Q3 2025.